Market Overview

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

Related PFE
Trans Pacific Trade Pact Finally Agreed
Broad Market New Highs For The Day, Pfizer Inc. On It's Low For The Day
Tarix Orphan's TXA127 Fast Track'd for DMD (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Pfizer closed on Thursday at $28.44.

Latest Ratings for PFE

Oct 2015Morgan StanleyUpgradesEqual-weightOverweight
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Downgrades Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters